Zero-fees brokerage revolution: Schwab and Ameritrade tie up to prepare for the fight

Introduction – Disruption in the industry The 2010s were a decade of incredible innovation in the financial industry, putting an enormous amount of pressure on the incumbent players and forcing them to make drastic decisions to survive. The securities brokerage industry was hit particularly high, as modern and affordable challengers Read more…

Want a robust quality drug pipeline? – Pay super premium!: Alexion to acquire Synageva in an $8.4bn deal

Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn   Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…